Switzerland
· Delayed Price · Currency is CHF RLF Statistics
Total Valuation
Relief Therapeutics Holding has a market cap or net worth of CHF 47.90 million. The enterprise value is 39.59 million.
| Market Cap | 47.90M |
| Enterprise Value | 39.59M |
Important Dates
The next estimated earnings date is Tuesday, April 1, 2025.
| Earnings Date | Apr 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Relief Therapeutics Holding has 12.54 million shares outstanding. The number of shares has increased by 14.39% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 12.54M |
| Shares Change (YoY) | +14.39% |
| Shares Change (QoQ) | +12.10% |
| Owned by Insiders (%) | 0.70% |
| Owned by Institutions (%) | 11.36% |
| Float | 9.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.55 |
| PB Ratio | 0.97 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.86 |
| EV / Sales | 4.60 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.81 |
Financial Position
The company has a current ratio of 3.09, with a Debt / Equity ratio of 0.05.
| Current Ratio | 3.09 |
| Quick Ratio | 2.45 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.23 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -64.38% and return on invested capital (ROIC) is -10.23%.
| Return on Equity (ROE) | -64.38% |
| Return on Assets (ROA) | -7.83% |
| Return on Capital (ROIC) | -10.23% |
| Revenue Per Employee | 175,469 |
| Profits Per Employee | -943,653 |
| Employee Count | 49 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 6.56 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +108.02% in the last 52 weeks. The beta is -14.74, so Relief Therapeutics Holding's price volatility has been lower than the market average.
| Beta (5Y) | -14.74 |
| 52-Week Price Change | +108.02% |
| 50-Day Moving Average | 5.02 |
| 200-Day Moving Average | 2.27 |
| Relative Strength Index (RSI) | 33.52 |
| Average Volume (20 Days) | 132,849 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Relief Therapeutics Holding had revenue of CHF 8.60 million and -46.24 million in losses. Loss per share was -3.70.
| Revenue | 8.60M |
| Gross Profit | 5.90M |
| Operating Income | -12.33M |
| Pretax Income | -51.54M |
| Net Income | -46.24M |
| EBITDA | -9.81M |
| EBIT | -12.33M |
| Loss Per Share | -3.70 |
Balance Sheet
The company has 10.73 million in cash and 2.42 million in debt, giving a net cash position of 8.31 million or 0.66 per share.
| Cash & Cash Equivalents | 10.73M |
| Total Debt | 2.42M |
| Net Cash | 8.31M |
| Net Cash Per Share | 0.66 |
| Equity (Book Value) | 49.27M |
| Book Value Per Share | 3.92 |
| Working Capital | 9.95M |
Cash Flow
In the last 12 months, operating cash flow was -10.31 million and capital expenditures -77,000, giving a free cash flow of -10.39 million.
| Operating Cash Flow | -10.31M |
| Capital Expenditures | -77,000 |
| Free Cash Flow | -10.39M |
| FCF Per Share | -0.83 |
Margins
| Gross Margin | 68.56% |
| Operating Margin | -143.38% |
| Pretax Margin | -599.43% |
| Profit Margin | n/a |
| EBITDA Margin | -114.13% |
| EBIT Margin | -143.38% |
| FCF Margin | -120.83% |
Dividends & Yields
Relief Therapeutics Holding does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.39% |
| Shareholder Yield | -14.39% |
| Earnings Yield | -96.93% |
| FCF Yield | -21.69% |
Stock Splits
The last stock split was on May 5, 2023. It was a reverse split with a ratio of 0.0025.
| Last Split Date | May 5, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.0025 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |